Lexicon Pharmaceuticals | LXRX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 9.21B 17M 2025-12
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Illumina USD 903M 69M 2025-12
Insmed USD 513.55M 109.86M 2025-12
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
J&J USD 18.97B 2.38B 2025-12
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
MannKind USD 119.64M 56.29M 2025-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Novartis USD 9.8B 61M 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Thermo Fisher Scientific USD 9.91B 867M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
United Therapeutics USD 804.8M 5.79B 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09